ImmunityBio drops as lawsuit headlines resurface after FDA flags Anktiva promotion
ImmunityBio shares slid as investors digested a fresh wave of securities class-action “investor alert” headlines tied to an FDA enforcement letter over Anktiva promotional claims. The FDA’s March 13, 2026 letter cited misleading ads and statements implying Anktiva could treat or prevent multiple cancers beyond its approved bladder-cancer use.
1. What’s moving the stock
ImmunityBio (IBRX) traded lower Wednesday as the market re-priced regulatory and litigation overhang tied to Anktiva marketing practices. Multiple class-action “investor alert” announcements circulated April 1, keeping attention on the FDA’s recent enforcement action and extending the negative tape that began after the late-March selloff. (prnewswire.com)
2. The catalyst investors are focused on
The FDA posted a letter dated March 13, 2026 addressing ImmunityBio’s promotional communications for Anktiva, including a direct-to-consumer TV ad and a podcast appearance. The agency said the materials created a misleading impression about efficacy beyond the approved indication and lacked required risk information, and it referenced prior untitled letters sent in 2025 and early 2026 related to similar issues. (fda.gov)
3. Why it matters from here
Even without a new clinical readout, enforcement actions around drug promotion can increase regulatory scrutiny and complicate commercialization narratives, especially for companies seeking label expansion. Separately, the continued drumbeat of class-action filings/solicitations can weigh on sentiment and amplify volatility as traders handicap potential legal costs and management distraction. (prnewswire.com)